Fazirsiran for mild liver scarring in alpha-1 antitrypsin deficiency
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a specific genetic type of alpha-1 antitrypsin deficiency called PiZZ (confirmed by a blood test or medical records).
- You must have mild liver scarring (stage F1) seen on a liver biopsy — a new biopsy can be done during the screening process.
- You cannot have more advanced liver scarring (stage F2 or higher), complications of cirrhosis, or other forms of chronic liver disease.
- You must not smoke and must not regularly use oxygen therapy (a CPAP for sleep apnea is allowed).
- You cannot have active infections with hepatitis B, hepatitis C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
This trial tests a new medicine called TSRA-196 for people with Alpha-1 Antitrypsin Deficiency who have the PiZZ genetic type. The study looks at whether TSRA-196 can help with lung or liver problems related to this condition.
Hear when a new Alpha1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.